Nektar Therapeutics (NKTR) Financials

NKTR Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 1.1 billion 192.0 million
March 31, 2026 763.3 million 187.1 million
Dec. 31, 2025 280.4 million 190.6 million
Sept. 30, 2025 301.3 million 216.3 million

NKTR Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -75.9 million 3.4 million
March 31, 2026 -44.3 million 3.4 million
Dec. 31, 2025 -65.0 million 2.2 million
Sept. 30, 2025 -48.9 million 3.1 million

NKTR Net Income

No data available :(

NKTR Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 684.3 million - -
March 31, 2026 568.6 million - 83.2 million
Dec. 31, 2025 245.8 million - 85.8 million
Sept. 30, 2025 270.2 million - 91.9 million

NKTR Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 33.1 million
March 31, 2026 24.7 million
Dec. 31, 2025 20.3 million
Sept. 30, 2025 14.1 million

NKTR Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 112000 39.1 million 12.8 million -
March 31, 2026 18000 35.7 million 13.4 million -151000
Dec. 31, 2025 18000 29.7 million 11.4 million -
Sept. 30, 2025 114000 27.3 million 15.9 million -

NKTR Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 10.1 million -
March 31, 2026 10.9 million 151000
Dec. 31, 2025 21.8 million -
Sept. 30, 2025 11.8 million 196000

NKTR Revenue by Segment
Graph available only for paid members. Upgrade to see it.

NKTR

Price: $36.04

52 week price:
33.40
109.00

Payout Ratio Range:
-34.70%
-0.18%

Earnings Per Share: -6.32 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 1.8 million

Ebitda: 74.9 million

Market Capitalization: 1.1 billion

Links: